Utilizing LNCaP prostate cancer cells, they found that the melatonin neither competitively inhibited the AR, nor affected steroid binding capacity, but did precipitate nuclear exclusion of the AR that they suggested to explain the attenuated AR activity evident by diminished androgen-induced transcriptional activity and downregulation of AR mRNA [66]. The gene discussed is AR; the disease is prostate cancer.